Posted by Michael Wonder on 10 Dec 2024
PHARMAC seeks feedback to fund medicines for liver and ovarian cancer
9 December 2024 - PHARMAC is consulting on a proposal to fund bevacizumab (branded as Vegzelma) as a cancer medicine for more New Zealanders.
In September, PHARMAC started a competitive procurement process to ask suppliers to bid to supply the main funded brand of bevacizumab and to see if access could be widened so more people could benefit from the medicine.
